Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) EBIAT (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBIAT for 16 consecutive years, with $52.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT fell 5.79% year-over-year to $52.7 million, compared with a TTM value of $214.3 million through Dec 2025, up 30.78%, and an annual FY2025 reading of $214.3 million, up 30.78% over the prior year.
  • EBIAT was $52.7 million for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from $52.8 million in the prior quarter.
  • Across five years, EBIAT topped out at $56.7 million in Q1 2025 and bottomed at -$30.8 million in Q3 2023.
  • Average EBIAT over 5 years is $28.6 million, with a median of $27.5 million recorded in 2022.
  • The sharpest move saw EBIAT plummeted 235.24% in 2023, then skyrocketed 242.65% in 2024.
  • Year by year, EBIAT stood at $9.3 million in 2021, then surged by 173.62% to $25.5 million in 2022, then surged by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025.
  • Business Quant data shows EBIAT for CPRX at $52.7 million in Q4 2025, $52.8 million in Q3 2025, and $52.1 million in Q2 2025.